The Valley Desk

NCT02186301 · Interventional trial

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Overall registry status Terminated

Phase 2 · Phase 3

Conditions Non-Small Cell Lung Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov